We hypothesized that the Taz-KO mouse would be biologically congruent with the human condition of BTHS, and therefore that the characterization of its functional and metabolic characteristics at 3, 6, and 12 months of age would provide important information on disease progression across the lifespan, and would also identify useful outcome measures for preclinical trials. Here, TAFAZZIN is linked to Barth syndrome.